ClinicalTrials.gg
CompletedNCT06277765Updated Oct 2, 2025

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

A Phase 3 interventional study of CM310 and placebo in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Keymed Biosciences Co.Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.

Enrollment
5th of 12
180 · median 170
Started
2024
with 1 other
Phase 3
5 of 12
2 open now
Registered
9th of 12
by date
Lead sponsor
12 of 12
Keymed Biosciences Co.Ltd

Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 5th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About stapokibart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing stapokibart in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have the ability to understand the study and voluntarily sign a written form (ICF).
  • With Atopic Dermatitis.

Exclusion criteria

Exclusion Criteria:

  • Not enough washing-out period for previous therapies.
  • Any major surgery planned during the research period.
  • With intestinal parasitic infection within the 6 months before screening.
  • With any circumstance that is not suitable to participate in this study.
  • Major surgeries are planned during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    CM310 group

    Biological: CM310

  • Placebo comparator
    Placebo

    Other: placebo

Interventions

  • BiologicalCM310

    Interleukin-4 receptor(IL-4Rα) monoclonal antibody

  • Otherplacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving EASI-75 at week 18

    The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, edema/papulation, excoriation, lichenification) will each be assessed for severity by the investigator on a scale of "0" (none) through "3" (severe).

    Time frame: Up to week 18

  2. Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline

    Proportion of subjects with Investigator's Global Assessment (IGA) score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline at week 18. IGA is an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe).

    Time frame: up to week 18

Secondary outcomes

  1. Percent change of Eczema Area and Severity Index (EASI) score from baseline

    The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) will each be assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe).

    Time frame: up to week 18

  2. Percent change of NRS score from baseline

    The range of Pruritus Numerical Rating Scale (NRS) is from 0 (no itch)-10 (worst imaginable itch)

    Time frame: up to week 18

  3. Body surface area (BSA) of involvement of atopic dermatitis

    Change from baseline in percent of BSA

    Time frame: up to week 18

  4. Children Dermatology Life Quality Index (CDLQI)

    Changes from baseline in CDLQI

    Time frame: up to week 18

  5. Patient-Oriented Eczema Measure (POEM)

    Changes from baseline in POEM

    Time frame: up to week 18

  6. EuroQol Five Dimensions Questionnaire (EQ-5D)

    Changes from baseline in EQ-5D

    Time frame: up to week 18

  7. Safety parameters

    Incidence of Adverse Event(AE), abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: up to week 26

  8. Pharmacokinetics parameters

    Trough concentration and exposure of CM310

    Time frame: up to week 26

  9. Pharmacodynamics

    Serum concentration of Thymus and activation regulated chemokine (TARC) , total immunoglobulin E (IgE) and lactate dehydrogenase (LDH)

    Time frame: up to week 26

  10. Immunogenicity

    Detection of anti-drug antibody (ADA)

    Time frame: up to week 26

07

Study locations

1 site
  • Peking University People's hospital
    Beijing, China
08

References and documents

Publications

  • Zhou C, Zhao Y, Zhu G, Wu L, Liu Y, Tao X, Zhao H, Wei Z, Lu W, Li W, Ding Y, Zhu X, Hu G, Cheng H, Xiao R, Man XY, Wang Q, Li S, Zeng T, Wang L, Xu Y, Zhang L, Liu W, Zhao G, Jia Y, Huang Y, Chen B, Zhang J. Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. Br J Dermatol. 2026 May 19;194(6):1067-1076. doi: 10.1093/bjd/ljag052. PubMed 41697953 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jan 2025, 10 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2024
First posted
Feb 26, 2024
StartActual
Mar 21, 2024
Primary completionActual
Jan 23, 2025
CompletionActual
Jan 23, 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06277765
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Mar 21, 2024
Primary completion
Jan 23, 2025
Completion
Jan 23, 2025
Last update
Oct 2, 2025

Study contacts

jianzhong Zhang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion